Iconovo AB (publ) (STO:ICO)

Market Cap	136.90M
Revenue (ttm)	19.39M
Net Income (ttm)	-43.52M
Shares Out	53.06M
EPS (ttm)	-2.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	169,864
Average Volume	115,622
Open	2.470
Previous Close	2.430
Day's Range	2.290 - 2.590
52-Week Range	0.951 - 9.000
Beta	0.47
RSI	70.34
Earnings Date	Oct 24, 2025

About Iconovo AB

Iconovo AB (publ) develops and licenses inhalation medications in Sweden. The company offers ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone Nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has collaboration agreement with Affilogic, ENA Respiratory Pty Ltd, Lonza, and Stevanato Group, as well as licensing agreements with Kiox Pharma and Monash Uni...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2013
• Employees: 25
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ICO

Financial Performance

In 2024, Iconovo AB's revenue was 24.00 million, a decrease of -14.62% compared to the previous year's 28.11 million. Losses were -41.14 million, -10.36% less than in 2023.